Vertex Pharmaceuticals (VRTX) to Release Quarterly Earnings on Monday

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) is scheduled to be issuing its quarterly earnings data after the market closes on Monday, November 4th. Analysts expect the company to announce earnings of $3.60 per share for the quarter. Vertex Pharmaceuticals has set its FY 2024 guidance at EPS.Parties that are interested in participating in the company's conference call can do so using this link.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its earnings results on Thursday, August 1st. The pharmaceutical company reported ($12.83) EPS for the quarter, missing the consensus estimate of ($12.54) by ($0.29). The company had revenue of $2.65 billion for the quarter, compared to the consensus estimate of $2.66 billion. Vertex Pharmaceuticals had a negative return on equity of 2.45% and a negative net margin of 4.74%. Vertex Pharmaceuticals's quarterly revenue was up 6.1% compared to the same quarter last year. During the same quarter last year, the business earned $3.53 EPS. On average, analysts expect Vertex Pharmaceuticals to post $-2 EPS for the current fiscal year and $16 EPS for the next fiscal year.

Vertex Pharmaceuticals Price Performance

Shares of Vertex Pharmaceuticals stock traded down $1.33 during midday trading on Monday, hitting $476.37. 498,202 shares of the company were exchanged, compared to its average volume of 1,167,927. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.52 and a quick ratio of 2.26. Vertex Pharmaceuticals has a 52 week low of $341.90 and a 52 week high of $510.64. The firm has a 50 day simple moving average of $475.61 and a 200-day simple moving average of $462.73.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs sold 5,295 shares of the business's stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $508.00, for a total value of $2,689,860.00. Following the completion of the transaction, the director now directly owns 40,000 shares of the company's stock, valued at approximately $20,320,000. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, Director Sangeeta N. Bhatia sold 646 shares of the company's stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $500.00, for a total transaction of $323,000.00. Following the completion of the transaction, the director now directly owns 4,435 shares of the company's stock, valued at $2,217,500. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bruce I. Sachs sold 5,295 shares of the company's stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $508.00, for a total value of $2,689,860.00. Following the transaction, the director now directly owns 40,000 shares of the company's stock, valued at $20,320,000. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 12,005 shares of company stock valued at $5,988,066. Company insiders own 0.20% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on VRTX shares. Piper Sandler lifted their price objective on Vertex Pharmaceuticals from $500.00 to $535.00 and gave the company an "overweight" rating in a research report on Friday, August 2nd. StockNews.com downgraded Vertex Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Monday, August 5th. Needham & Company LLC reiterated a "hold" rating on shares of Vertex Pharmaceuticals in a research report on Friday, July 26th. Morgan Stanley lifted their price objective on Vertex Pharmaceuticals from $462.00 to $474.00 and gave the company an "equal weight" rating in a research report on Tuesday, October 1st. Finally, Scotiabank started coverage on Vertex Pharmaceuticals in a research report on Wednesday, October 16th. They issued a "sector perform" rating and a $480.00 price objective for the company. Three research analysts have rated the stock with a sell rating, ten have given a hold rating and seventeen have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $492.92.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.